

## 해외 바이오의약품 임상 현황 (2021.2.1~2021.2.7)

한국바이오의약품협회, 2021.2.9.  
출처: ClinicalTrials.gov

### ○ 미국 57건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04722601	A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma	Follicular Lymphoma	Drug: Venetoclax Drug: Obinutuzumab Drug: CC-486	University of Chicago	Phase 1  Phase 2	_____
NCT04684641	Cystic Fibrosis bacterioPhage Study at Yale (CYPHY)	Cystic Fibrosis	Drug: Standard Dose YPT-01 Drug: High Dose YPT-01 Other: Placebo	Yale University	Phase 1  Phase 2	_____
NCT04571970	RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)	Mucopolysaccharidosis Type II (MPS II)	Genetic: RGX-121	Regenxbio Inc.	Phase 1  Phase 2	_____
NCT04548791	Study of Coagulation Factor Villa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders	Factor VII Deficiency Glanzmann Thrombasthenia Hemophilia A With Inhibitor	Biological: Coagulation Factor Villa variant	Catalyst Biosciences	Phase 1  Phase 2	_____
NCT04285671	Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer	Metastatic Lung Non-Small Cell Carcinoma Refractory Lung Non-Small Cell Carcinoma Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8	Biological: Necitumumab Drug: Osimertinib Other: Quality-of-Life Assessment Other: Questionnaire Administration Biological: Trastuzumab	Jonsson Comprehensive Cancer Center Eli Lilly and Company Genentech, Inc.	Phase 1  Phase 2	_____
NCT04085887	Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures	Brain Tumor	Drug: Panitumumab-IRDye800 Device: Pinpoint-IR9000 endoscopic/handheld device Device: Explorer Air camera Device: PDE-NEO-II	Stanford University	Phase 1  Phase 2	_____
NCT04739618	Metastatic Solid Cancer Clinical Trial	Metastatic Cancer	Drug: Keytruda Injectable Product Drug: Yervoy Injectable Product Drug: GM-CSF Procedure: Non-ablative Cryosurgical freezing	ImmunSYS, LLC	Phase 2	_____
NCT04737460	Study for the Treatment for CLN7 Disease	CLN7	Genetic: AAV9/CLN7	Benjamin Greenberg University of Texas Southwestern Medical Center	Phase 1	_____
NCT04737161	Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome	Acute Respiratory Distress Syndrome Covid19	Biological: T regulatory cells	Stanford University	Phase 1	_____
NCT04732845	Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies	Non Hodgkin Lymphoma Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia	Biological: Fully human anti CD19 CAR-T Cell Dose Drug: Fludarabine Drug: Cyclophosphamide	Paolo Caimi, MD Case Comprehensive Cancer Center	Phase 1	_____
NCT04732468	COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA	Covid19	Biological: hAd5-S-Fusion+N-ETSD (Suspension for injection) Drug: hAd5-SFusion+ N-ETSD (Oral capsule)	ImmunityBio, Inc.	Phase 1	_____
NCT04708886	Romosozumab in Women With Chronic SCI	Osteoporosis Bone Loss Osteopenia, Osteoporosis Spinal Cord Injuries Chronic Spinal Paralysis	Drug: Romosozumab Drug: Alendronate	Northwestern University Amgen	Phase 2	_____
NCT04700176	A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma	Multiple Myeloma	Drug: Daratumumab Drug: Pomalidomide Drug: All-trans retinoic acid Drug: Dexamethasone	Hackensack Meridian Health Janssen, LP	Phase 2	_____
NCT04698187	CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma	Melanoma Advanced Melanoma Metastatic Melanoma Unresectable Melanoma	Drug: CMP-001 Drug: Nivolumab	Checkmate Pharmaceuticals QVIA Biotech	Phase 2	_____
NCT04697576	Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma	Clinical Stage I Cutaneous Melanoma AJCC v8 Clinical Stage IA Cutaneous Melanoma AJCC v8 Clinical Stage IB Cutaneous Melanoma AJCC v8 Clinical Stage II Cutaneous Melanoma AJCC v8 Clinical Stage IIA Cutaneous Melanoma AJCC v8 Clinical Stage IIB Cutaneous Melanoma AJCC v8 Clinical Stage IIC Cutaneous Melanoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Metastatic Melanoma	Biological: Ipilimumab Biological: Nivolumab Biological: Pembrolizumab Biological: Quadrivalent Inactivated Influenza Vaccine Procedure: Resection	Carlo Contreras Ohio State University Comprehensive Cancer Center	Phase 1	_____
NCT04684563	huCART19-IL18 in NHL/CLL Patients	Chronic Lymphocytic Leukemia Non-hodgkin Lymphoma	Biological: huCART19-IL18	University of Pennsylvania	Phase 1	_____
NCT04658147	Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)	Hepatocellular Carcinoma	Drug: Nivolumab Drug: Relatlimab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 1	_____
NCT04616248	Radio-immunotherapy (CDX-301, Radiotherapy, CDX-1140 and Poly-ICLC) for the Treatment of Unresectable or Metastatic Breast Cancer Patients	Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8 Unresectable Breast Carcinoma	Biological: Anti-CD40 Agonist Monoclonal Antibody CDX-1140 Drug: Poly ICLC Radiation: Radiation Therapy Biological: Recombinant Flt3 Ligand	Roswell Park Cancer Institute	Phase 1	_____
NCT04558736	Haploidentical HCT for Severe Aplastic Anemia	Aplastic Anemia Bone Marrow Failure Syndrome Dyskeratosis Congenita	Drug: Anti-Thymocyte Globulin (Rabbit) Drug: Fludarabine Drug: Cyclophosphamide Drug: Mesna Drug: G-CSF Radiation: Total Lymphoid Irradiation (TLI) Device: CliniMACS Biological: HPC, A Infusion Biological: CD45RA-depleted DU	St. Jude Children's Research Hospital	Phase 2	_____
NCT04547777	Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma	Glioma, Malignant	Drug: D2C7-IT Drug: 2141-V11	Darell Bigner Rockefeller University Duke University	Phase 1	_____
NCT04517851	Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis	Myelofibrosis Transformation in Essential Thrombocythemia Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase Primary Myelofibrosis	Biological: Elotuzumab Other: Questionnaire Administration	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1	_____
NCT04506554	A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer	Muscle-Invasive Bladder Carcinoma	Drug: AMVAC + Nivolumab	Fox Chase Cancer Center	Phase 2	_____
NCT04450173	Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma	Ann Arbor Stage II Follicular Lymphoma Ann Arbor Stage III Follicular Lymphoma Ann Arbor Stage IV Follicular Lymphoma Grade 1 Follicular Lymphoma Grade 2 Follicular Lymphoma Grade 3a Follicular Lymphoma	Drug: Ibrutinib Biological: Obinutuzumab Drug: Venetoclax	Joseph Tuscano National Cancer Institute (NCI) Pharmacyclics LLC Genentech, Inc. University of California, Davis	Phase 2	_____
NCT04348747	Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Malignant Neoplasm in the Brain Metastatic Triple-Negative Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8	Biological: Anti-HER2/HER3 Dendritic Cell Vaccine Drug: Celecoxib Biological: Pembrolizumab Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2	_____
NCT04301778	Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma	Unresectable Intrahepatic Cholangiocarcinoma	Drug: Durvalumab Drug: SNDX-6352	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Syndax Pharmaceuticals AstraZeneca	Phase 2	_____
NCT04238091	Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata	Alopecia Areata Alopecia Totalis Alopecia Universalis	Drug: Fecal material transfer therapy Procedure: 4mm Punch Biopsy of Scalp Diagnostic Test: Blood draw Procedure: Skin Microbiome sampling Procedure: Hair Microbiome Sampling Drug: Pre-FMT Antibiotic Cocktail Drug: Bowel Prep	Columbia University	Phase 2	_____
NCT04182490	LMN-101 in a Campylobacter Human Challenge Model	Campylobacter Infections	Biological: LMN-101	Lumen Bioscience, Inc. Naval Medical Research Center Pharmaron CPC, Inc. University of Maryland, College Park	Phase 2	_____
NCT04171622	Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer	Metastatic Thyroid Gland Carcinoma Poorly Differentiated Thyroid Gland Carcinoma Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8 Thyroid Gland Squamous Cell Carcinoma Unresectable Thyroid Gland Carcinoma	Drug: Lenvatinib Biological: Pembrolizumab	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2	_____
NCT04102436	Non-Viral TCR Gene Therapy	Glioblastoma Non-Small Cell Lung Cancer Breast Cancer Gastrointestinal/Genitourinary Cancer Ovarian Cancer	Drug: Fludarabine Drug: Cyclophosphamide Drug: Aldesleukin Biological: Sleeping Beauty Transposed PBL	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 2	_____
NCT04059757	Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD	Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)	Biological: Fecal Microbiota Transplantation (FMT)	Leland Metheny Case Comprehensive Cancer Center	Phase 2	_____
NCT04038619	Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients	Colitis Diarrhea Malignant Genitourinary System Neoplasm	Procedure: Fecal Microbiota Transplantation Drug: Loperamide	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1	_____
NCT03943901	Split-Dose R-CHOP for Older Adults With DLBCL	Diffuse Large B Cell Lymphoma DLBCL Cancer	Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Biological: Pegfilgrastim	University of Wisconsin, Madison Medical College of Wisconsin	Phase 2	_____

## 해외 바이오의약품 임상 현황 (2021.2.1~2021.2.7)

한국바이오의약품협회, 2021.2.9.  
출처: ClinicalTrials.gov

NCT03522545	Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression	Treatment-resistant Bipolar Depression	Biological: Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) Biological: Placebo	The University of Texas Health Science Center, Houston	Phase 1	_____
NCT03258658	Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures	Urologic Diseases Male Urogenital Diseases Urethral Stricture Urethral Injury	Biological: Autologous Engineered Urethral Construct	Wake Forest University Health Sciences United States Department of Defense	Phase 1	_____
NCT04664179	EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma	EBV-Related Hodgkin Lymphoma Lymphoproliferative Disorders Chronic EBV (Epstein-Barr Virus) Infection Syndrome EBV Related Non-Hodgkin's Lymphoma	Biological: Dose Level 1A: 2 x 10^7 cells/m2 Biological: Dose Level 2A: 6 x 10^7 cells/m2 Biological: Dose Level 3A: 2 x 10^8 cells/m2 Biological: Dose Level 2B Biological: Dose Level 3B	Baylor College of Medicine The Methodist Hospital System	Phase 1	_____
NCT04660929	CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors	HER2-positive Adenocarcinoma Bile Duct Cancer Biliary Tract Cancer Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Ductal Carcinoma, Hepatocellular Cancer Carcinoma, Non-Small-Cell Lung Carcinoma, Ovarian Epithelial Carcinoma, Small Cell Carcinoma, Squamous Carcinoma, Transitional Cell Colorectal Cancer Esophagogastric Junction Neoplasms Inflammatory Breast Cancer Stomach Neoplasms Malignant Neoplasms Ovarian Neoplasms Pancreatic Cancer HER2-positive Solid Tumors HER2-positive Breast Cancer HER2-positive Gastric Cancer HER-2 Protein Overexpression HER-2 Gene Amplification	Biological: CT-0508	Carisma Therapeutics Inc	Phase 1	_____
NCT04607200	AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma	Angiosarcoma	Drug: AGEN2034 Drug: AGEN1884	Agenus Inc.	Phase 2	_____
NCT04559230	Sacituzumab Govitecan in Recurrent Glioblastoma	Glioblastoma	Drug: Sacituzumab Govitecan	The University of Texas Health Science Center at San Antonio	Phase 2	_____
NCT04448834	Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphia CD19+ ALL	B-cell Acute Lymphoblastic Leukemia	Drug: Blinatumomab	David Rizzieri, MD Amgen Acrotech Biopharma LLC Duke University	Phase 2	_____
NCT04268706	Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)	Hodgkin Lymphoma, Adult Hodgkin Disease Recurrent Hodgkin Disease Refractory Hodgkin Disease, Pediatric	Drug: CD30.CAR-T Drug: Fludarabine Drug: Bendamustine	Tessa Therapeutics	Phase 2	_____
NCT04618393	A Study of EMB-02 in Participants With Advanced Solid Tumors	Advanced Solid Tumors	Biological: EMB-02	Shanghai EpimAb Biotherapeutics Co., Ltd.	Phase 1  Phase 2	_____
NCT04598477	A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)	Pemphigus Vulgaris Pemphigus Foliaceus	Biological: efgartigimod PH20 SC Drug: prednisone	argenx	Phase 3	_____
NCT04734873	CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients	Covid-19	Drug: CPI-006 2 mg/kg + SOC Drug: CPI-006 1 mg/kg + SOC Drug: Placebo + SOC	Corvus Pharmaceuticals, Inc.	Phase 3	_____
NCT04688853	A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients	Multiple Myeloma, Refractory Multiple Myeloma in Relapse Multiple Myeloma	Biological: TEG002	Gadeta B.V.	Phase 1	_____
NCT04554914	A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases	Epstein-Barr Virus (EBV)-Associated Diseases EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (PID LPD) EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (AID LPD) EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (CNS PTLD) EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD) Solid Organ Transplant Complications Lymphoproliferative Disorders Allogeneic Hematopoietic Cell Transplant Stem Cell Transplant Complications EBV+ Sarcomas Leiomyosarcoma Chronic Active Epstein-Barr Virus (CAEBV) Chronic Active Epstein-Barr Virus With Hemophagocytic Lymphohistiocytosis (HLH) Lymphohistiocytosis, Hemophagocytic	Biological: Tabelecleucel	Atara Biotherapeutics	Phase 2	_____
NCT04549285	Infusions of Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome	Multisystem Inflammatory Syndrome in Children	Biological: Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)	Joanne Kurtzberg, MD Duke University	Phase 1	_____
NCT04665206	Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations	Solid Tumor, Adult Mesothelioma	Drug: VT3989	Vivace Therapeutics, Inc	Phase 1	_____
NCT04270175	Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab	Amyloid AL Amyloidosis Refractory AL Amyloidosis	Drug: Daratumumab Drug: Pomalidomide Drug: Dexamethasone	Weill Medical College of Cornell University Janssen Scientific Affairs, LLC	Phase 2	_____
NCT04260126	Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC	Metastatic Head and Neck Cancer Recurrent Head and Neck Cancer HPV Positive Oropharyngeal Squamous Cell Carcinoma HPV-Related Esophageal Squamous Cell Carcinoma Neoplasms, Head and Neck	Combination Product: Pembrolizumab and PDS0101	PDS Biotechnology Corp. Merck Sharp & Dohme Corp.	Phase 2	_____
NCT04557384	A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer	Advanced Solid Tumor	Drug: Ramucirumab	Eli Lilly and Company	Phase 1	_____
NCT04594642	A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	B-cell Non Hodgkin Lymphoma Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma Follicular Lymphoma	Drug: TNB-486	Teneobio, Inc.	Phase 1	_____
NCT04300140	Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Clear Cell Renal Cell Carcinoma	Clear Cell Renal Cell Carcinoma	Drug: AVB-S6-500 Drug: Cabozantinib (Cabo)	Aravive, Inc.	Phase 1  Phase 2	_____
NCT04722172	A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL	Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma	Drug: Acalabrutinib Drug: Obinutuzumab	Memorial Sloan Kettering Cancer Center AstraZeneca Genentech, Inc.	Phase 2	_____
NCT04374253	A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)	Alzheimer Disease	Drug: Gantenerumab	Hoffmann-La Roche	Phase 3	_____
NCT04444895	A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor	Angioedema	Drug: Lanadelumab	Shire Takeda Development Center Americas, Inc Takeda	Phase 3	_____
NCT04741087	Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis	Pouchitis	Drug: AMT-101 (oral)-Dose A Drug: AMT-101 (oral)-Dose B	Applied Molecular Transport	Phase 2	_____
NCT04702880	A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer	Extensive-stage Small Cell Lung Cancer	Biological: BMS-986012 Drug: Carboplatin Drug: Etoposide Biological: Nivolumab	Bristol-Myers Squibb	Phase 2	_____

### ○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04443829	No Results Available	Primary CNS Lymphoma	Biological: CD19CAR T-cells	University College, London	Phase 1	_____

## 해외 바이오의약품 임상 현황 (2021.2.1~2021.2.7)

한국바이오의약품협회, 2021.2.9.  
출처: ClinicalTrials.gov

### ○ 프랑스 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04651439	Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma (CAROUSEL)	Rare Diseases Toxic Epidermal Necrolyses	Drug: Filgrastim Drug: Placebo	Hospices Civils de Lyon	Phase 2  Phase 3	_____
NCT04725331	A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors	Solid Tumor, Adult Metastatic Cancer Soft Tissue Sarcoma Merkel Cell Carcinoma Melanoma Triple Negative Breast Cancer Non Small Cell Lung Cancer	Biological: BT-001 Biological: Pembrolizumab [Keytruda]	Transgene BioInvent International AB	Phase 1  Phase 2	_____
NCT04428047	Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma (ICING)	Squamous Cell Carcinoma of Head and Neck	Drug: bintrafusp alfa	UNICANCER Merck KGaA, Darmstadt, Germany	Phase 2	_____
NCT04741087	Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis (FILLMORE)	Pouchitis	Drug: AMT-101 (oral)-Dose A Drug: AMT-101 (oral)-Dose B	Applied Molecular Transport	Phase 2	_____

### ○ 독일 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04727541	Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer	Biliary Tract Cancer Cholangiocarcinoma	Drug: Bintrafusp alfa	AIO-Studien-gGmbH Merck Serono GmbH, Germany	Phase 2	_____
NCT04628026	Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2	Acute Myeloid Leukemia Myelodysplastic Syndromes	Drug: Venetoclax Drug: Placebo Combination Product: Standard chemotherapy Other: Autologous stem cell transplantation Other: Allogeneic stem cell transplantation	University of Ulm Stichting Hemato-Oncologie voor Volwassenen Nederland	Phase 3	_____

### ○ 중국 20건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04686929	Abatacept s.c. for aGVHD Prevention in Haplo-HCT	Abatacept Acute-graft-versus-host Disease Haplo-identical HCT Prevention	Drug: Lower dose of abatacept Drug: Higher dose of abatacept	The First Affiliated Hospital of Soochow University	Phase 1  Phase 2	_____
NCT04637698	OH2 Oncolytic Viral Therapy in Pancreatic Cancer	Pancreatic Cancer	Biological: OH2 injection	Wuhan Binhui Biotechnology Co., Ltd.	Phase 1  Phase 2	_____
NCT04738981	Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT	Graft Vs Host Disease	Drug: UC-MSC Drug: Anti-CD25 mAb	Peking University People's Hospital Southern Medical University, China Third Military Medical University Sun Yat-sen University	Phase 3	_____
NCT04736823	A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC	NSCLC	Drug: AK112 Drug: Pemetrexed Drug: Paclitaxel Drug: Carboplatin Drug: Docetaxel Drug: AK105	Akeso	Phase 2	_____
NCT04736810	A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma	Nasopharyngeal Carcinoma	Biological: AK105 Drug: Cisplatin Drug: Gemcitabine Drug: Anlotinib hydrochloride	Akeso Akeso Tiancheng, Inc	Phase 2	_____
NCT04736589	Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway	Breast Cancer	Drug: Inetetamab Drug: Rapamycin Drug: Pyrotinib Drug: Chemotherapy	Peking Union Medical College	Phase 3	_____
NCT04735861	Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma	Ovarian Clear Cell Carcinoma	Drug: Sintilimab Drug: Bevacizumab Biosimilar IB1305	Tongji Hospital Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology Qilu Hospital of Shandong University The First Affiliated Hospital of Zhengzhou University Henan Cancer Hospital Hubei Cancer Hospital Shengjing Hospital Anhui Provincial Cancer Hospital Wuhan University Jingzhou Central Hospital The First People's Hospital of Jingzhou Xiangyang Central Hospital	Phase 2	_____
NCT04733963	Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer	Colorectal Cancer	Drug: Fruquintinib Plus Capecitabine Drug: Bevacizumab Plus Capecitabine	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2	_____
NCT04722718	Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer	Breast Cancer	Drug: Sintilimab+Apatinib+Albumin paclitaxel+Carboplatin	Jiuda Zhao Affiliated Hospital of Qinghai University	Phase 2	_____
NCT04720131	Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Unresectable Biliary Tract Cancer.	Biliary Tract Cancer Programmed Cell Death 1 Ligand 1 Gene Mutation Targeted Molecular Therapy Capecitabine	Drug: Camrelizumab Drug: apatinib Drug: Capecitabine	Beijing Friendship Hospital	Phase 2	_____
NCT04718701	Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer	Pancreatic Neoplasm Metastatic Pancreatic Cancer Locally Advanced Pancreatic Adenocarcinoma	Drug: Anlotinib+Toripalimab+Nab-paclitaxel	The First Affiliated Hospital with Nanjing Medical University	Phase 2	_____
NCT04718467	Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)	COVID-19	Biological: Recombinant COVID-19 vaccine (Sf9 cells) Biological: Placebo	Jiangsu Province Centers for Disease Control and Prevention West China Hospital	Phase 2	_____
NCT04708210	Study of the Efficacy and Safety of IB1319 in Patients With Advanced Malignant Tumors	Advanced Malignant Tumors	Drug: IB1319	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1	_____
NCT04706936	Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma	Relapsed or Refractory Multiple Myeloma	Biological: anti-BCMA CAR-T Drug: Cyclophosphamide Drug: Fludarabine	Second Affiliated Hospital, School of Medicine, Zhejiang University Carbiogene Therapeutics Co. Ltd.	Phase 1	_____
NCT04689659	Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Malignancies	T-cell Leukemia Refractory Leukemia Relapse Leukemia	Biological: chimeric antigen receptor T cell treatment	Beijing Boren Hospital	Phase 2	_____
NCT04670913	Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy	Advanced Non Squamous NSCLC	Drug: Camrelizumab Drug: Apatinib	Junling Li Peking Union Medical College	Phase 2	_____
NCT04605562	Umbrella Biomarker-Guided Therapy in NPC	Nasopharyngeal Carcinoma	Drug: GP+DDP Drug: Palbociclib Radiation: Intensity-modulated radiotherapy Drug: PD-1 blocking antibody Drug: Galunisertib	Sun Yat-sen University	Phase 2	_____
NCT04421352	Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients	Relapsed Small Cell Lung Cancer	Drug: CS1001	CStone Pharmaceuticals	Phase 1	_____
NCT04706598	Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment	Urinary Bladder Neoplasms Immunotherapy	Drug: Camrelizumab	Fudan University Shanghai Shen Kang Hospital Development Center	Phase 1  Phase 2	_____
NCT04718883	CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma	Mantle Cell Lymphoma	Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells	Shanghai Ming Ju Biotechnology Co., Ltd.	Phase 2	_____

### ○ 일본 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04689594	A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group	Superficial Esophageal Cancer	Combination Product: CLS2702C/CLS2702D	CellSeed Inc.	Phase 3	_____
NCT04696809	A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma	Hematologic Malignancies	Drug: Teclistamab	Janssen Pharmaceutical K.K.	Phase 1	_____
NCT04374253	A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)	Alzheimer Disease	Drug: Gantenerumab	Hoffmann-La Roche	Phase 3	_____
NCT04557384	A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer	Advanced Solid Tumor	Drug: Ramucirumab	Eli Lilly and Company	Phase 1	_____